Biogen Inc

NASDAQ:BIIB   2:43:51 PM EDT
287.14
-1.96 (-0.68%)
Products, Regulatory

Eisai And Biogen Announced Positive Topline Results From Eisai’S Large Global Phase 3 Confirmatory Clarity Ad Clinical Trial Of Lecanemab

Published: 09/27/2022 23:39 GMT
Biogen Inc (BIIB) - Eisai Co Ltd - Co, Biogen Announced Positive Topline Results From Eisai’s Large Global Phase 3 Confirmatory Clarity Ad Clinical Trial of Lecanemab.
Eisai Co Ltd - Lecanemab Met Primary Endpoint, Met All Key Secondary Endpoints in Confirmatory Phase 3 Clarity Ad Study.
Eisai Co Ltd - Profile of Amyloid-related Imaging Abnormalities (aria) Incidence Was Within Expectations in Confirmatory Phase 3 Clarity Ad Study.
Eisai Co Ltd - Co Aims to File for Traditional Approval in U.S., to Submit Marketing Authorization Applications in Japan,europe by End of Eisai FY2022.
Eisai Co Ltd - Study Showed Highly Statistically Significant Reduction of Clinical Decline in Clinical Study of Participants With Early Alzheimer’s Disease.